Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Anastasios G. Konstas, Antoine Labbé, Andreas Katsanos, Frances Meier-Gibbons, Murat Irkec, Konstadinos G. Boboridis, Gábor Holló, Julián García-Feijoo, Gordon N. Dutton & Christophe Baudouin. (2021) The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. Expert Opinion on Drug Safety 20:4, pages 453-466.
Read now
Read now
Rong Zhu, XiaoBo Zheng, LiLi Guo, YiPing Zhao, Yuan Wang, Jie Wu, AYong Yu, JunJie Wang, FangJun Bao & Ahmed Elsheikh. (2021) Biomechanical Effects of Two Forms of PGF2α on Ex-vivo Rabbit Cornea. Current Eye Research 46:4, pages 452-460.
Read now
Read now
Daisuke Inoue, Yasser Helmy Mohamed, Masafumi Uematsu & Takashi Kitaoka. (2020) Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops. Cutaneous and Ocular Toxicology 39:2, pages 158-164.
Read now
Read now
XiaoBo Zheng, Yuan Wang, YiPing Zhao, Si Cao, Rong Zhu, Wei Huang, AYong Yu, JinHai Huang, QinMei Wang, JunJie Wang, FangJun Bao & Ahmed Elsheikh. (2019) Experimental Evaluation of Travoprost-Induced Changes in Biomechanical Behavior of Ex-Vivo Rabbit Corneas. Current Eye Research 44:1, pages 19-24.
Read now
Read now
Jie Shen & Marina Bejanian. (2016) Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon. Clinical Ophthalmology 10, pages 373-383.
Read now
Read now
Luís F. Neves, Jinghua Duan, Adrienne Voelker, Anil Khanal, Lacey McNally, Jill Steinbach-Rankins & Brian P. Ceresa. (2016) Preparation and optimisation of anionic liposomes for delivery of small peptides and cDNA to human corneal epithelial cells. Journal of Microencapsulation 33:4, pages 391-399.
Read now
Read now
Albert Alm. (2014) Latanoprost in the treatment of glaucoma. Clinical Ophthalmology 8, pages 1967-1985.
Read now
Read now
Afshin Shafiee, Lyle M Bowman, Eddie Hou & Kamran Hosseini. (2013) Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes. Clinical Ophthalmology 7, pages 1549-1556.
Read now
Read now
Yang Liu & Weiming Mao. (2013) Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma. Clinical Ophthalmology 7, pages 7-14.
Read now
Read now
Articles from other publishers (35)
Srini VenkateshMary Richardson. (2023) Pharmacokinetic and Ocular Toxicity Evaluation of Latanoprost Ophthalmic Solution, 0.005%, with Preservative Level Reduced to Below the Limit of Quantitation. Journal of Ocular Pharmacology and Therapeutics 39:9, pages 622-630.
Crossref
Crossref
Anne Hedengran & Miriam Kolko. (2023) The molecular aspect of anti-glaucomatous eye drops - are we harming our patients?. Molecular Aspects of Medicine 93, pages 101195.
Crossref
Crossref
Minna Parkkari, Petri Purola & Hannu Uusitalo. (2022) Ocular surface disease signs and symptoms of glaucoma patients and their relation to glaucoma medication in Finland. European Journal of Ophthalmology 33:2, pages 993-1002.
Crossref
Crossref
Nupur Vasdev, Nakshatra Chaudhari, Suryanarayana Polaka, Kuldeep Rajpoot, Piyush Gondaliya, Adil Ali Sayyed, Pinaki Sengupta & Rakesh Kumar Tekade. (2023) Current progress in preservative-free topical ophthalmic formulations. Journal of Drug Delivery Science and Technology 79, pages 103996.
Crossref
Crossref
Julia Tau, María Silvia Passerini, Melina del Papa, Alejandro Aguilar & Alejandro Berra. (2022) A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study. Graefe's Archive for Clinical and Experimental Ophthalmology 260:6, pages 1941-1946.
Crossref
Crossref
JunJie Wang, YiPing Zhao, AYong Yu, Jie Wu, ManMan Zhu, MuChen Jiang, Xuefei Li, DaTian Zhu, PeiPei Zhang, XiaoBo Zheng, FangJun Bao & Ahmed Elsheikh. (2022) Effect of travoprost, latanoprost and bimatoprost PGF2α treatments on the biomechanical properties of in-vivo rabbit cornea. Experimental Eye Research 215, pages 108920.
Crossref
Crossref
FangJun Bao, Wen Chen, XiaoBo Zheng, YuanYuan Miao, ManMan Zhu, Stephen Akiti, YiXin Li, ZiHan Weng, JunJie Wang, PeiPei Zhang, ShiHao Chen & Ahmed Elsheikh. (2021) Changes in Corneal Biomechanical Properties in PRK Followed by Two Accelerated CXL Energy Doses in Rabbit Eyes. Journal of Refractive Surgery 37:12, pages 853-860.
Crossref
Crossref
Imran Mohammed, Bina Kulkarni, Lana A. Faraj, Ali Abbas, Harminder S. Dua & Anthony J. King. (2020) Profiling ocular surface responses to preserved and non‐preserved topical glaucoma medications: A 2‐year randomized evaluation study. Clinical & Experimental Ophthalmology 48:7, pages 973-982.
Crossref
Crossref
Monika Yadav, Ana Guzman-Aranguez, Maria J. Perez de Lara, Mandeep Singh, Joga Singh & Indu Pal Kaur. (2019) Safety data on in situ gelling bimatoprost loaded nanovesicular formulations. Data in Brief 25, pages 104361.
Crossref
Crossref
Gemma Caterina Maria Rossi, Luigia Scudeller, Chiara Lumini, Alessandra Venera Mirabile, Erica Picasso, Federica Bettio, Gian Maria Pasinetti & Paolo Emilio Bianchi. (2019) An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy. Scientific Reports 9:1.
Crossref
Crossref
Saoirse McCrann, Ian Flitcroft, Niall C. Strang, Kathryn J. Saunders, Nicola S. Logan, Samantha Szeyee Lee, David A. Mackey, John S. Butler & James Loughman. (2019) Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol. HRB Open Research 2, pages 15.
Crossref
Crossref
David W Steven, Pouya Alaghband & Kin Sheng Lim. (2018) Preservatives in glaucoma medication. British Journal of Ophthalmology 102:11, pages 1497-1503.
Crossref
Crossref
Laura M. Dutca, Danielle Rudd, Victor Robles, Anat Galor, Mona K. Garvin & Michael G. Anderson. (2018) Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice. Scientific Reports 8:1.
Crossref
Crossref
Yumi HashimotoSeiichi YokooTomohiko UsuiYukiko Tsubota & Satoru Yamagami. (2017) High Permeability and Intercellular Space Widening With Brimonidine Tartrate Eye Drops in Cultured Stratified Human Corneal Epithelial Sheets. Cornea 37:2, pages 242-247.
Crossref
Crossref
N. V. Makashova, A. E. Vasilieva & O. Yu. Kolosova. (2018) Effects of artificial tears on ocular surface in glaucomatous patients with long-term instillation of preserved antiglaucoma eye drops. Vestnik oftal'mologii 134:2, pages 59.
Crossref
Crossref
Elham Ghahari, Ali R. Djalilian & Ahmad A. Aref. 2018. Ocular Surface Disease. Ocular Surface Disease
125
138
.
Francisco Pérez-Bartolomé, Jose M. Martínez-de-la-Casa, Pedro Arriola-Villalobos, Cristina Fernández-Pérez, Vicente Polo & Julián García-Feijoó. (2017) Ocular Surface Disease in Patients under Topical Treatment for Glaucoma. European Journal of Ophthalmology 27:6, pages 694-704.
Crossref
Crossref
Anna Trzeciecka, J. Jussi Paterno, Elisa Toropainen, Ali Koskela, Lucia Podracka, Eveliina Korhonen, Anu Kauppinen, Kai Kaarniranta & Adrian Smedowski. (2016) Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa. European Journal of Pharmacology 788, pages 12-20.
Crossref
Crossref
Jenni J. Hakkarainen, Mika Reinisalo, Symantas Ragauskas, Aila Seppänen, Simon Kaja & Giedrius Kalesnykas. (2016) Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. International Journal of Pharmaceutics 511:1, pages 73-78.
Crossref
Crossref
Masamichi Fukuda, Nobuo Takeda, Shinsuke Shibata, Naoko Shibata, Teppei Shibata, Kazuhisa Sugiyama & Hiroshi Sasaki. (2016) In vitro and in vivo corneal effects of latanoprost combined with brimonidine, timolol, dorzolamide, or brinzolamide. European Journal of Pharmacology 787, pages 43-46.
Crossref
Crossref
Yoshihiko Esaki, Atsushi Shimazaki & Pertti Pellinen. (2016) Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study. The Open Ophthalmology Journal 10:1, pages 146-153.
Crossref
Crossref
Kai Kaarniranta, Kirsi Ikäheimo, Eliisa Mannermaa & Auli Ropo. (2015) Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015 % and Timolol 0.5 % in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. Clinical Pharmacokinetics 55:4, pages 485-494.
Crossref
Crossref
Fernando Pérez-Roca, Esther Rodrigo-Morales, Ingrid Garzón, Ana-Celeste Oliveira, Miguel-Ángel Martín-Piedra, Víctor Carriel, Ana-Isabel Ortiz-Pérez, Indalecio Sánchez-Montesinos, Antonio Campos & Miguel Alaminos. (2015) Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study. PLOS ONE 10:6, pages e0129419.
Crossref
Crossref
Caitlin Chang, Angela Q Zhang, Dov B Kagan, Hong Liu & Cindy ML Hutnik. (2015) Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative-free tafluprost. Clinical & Experimental Ophthalmology 43:2, pages 164-172.
Crossref
Crossref
Ana Guzman-AranguezPatricia CalvoInés RoperoJesús Pintor. (2014)
In Vitro
Effects of Preserved and Unpreserved Anti-Allergic Drugs on Human Corneal Epithelial Cells
. Journal of Ocular Pharmacology and Therapeutics 30:9, pages 790-798.
Crossref
Crossref
Takeshi KumagamiHarumi WakiyamaMao KusanoAyano KajiyamaYoko MiuraMasafumi UematsuAi YonedaJunko KuriharaKiyoshi SuzumaTakashi Kitaoka. (2014) Comparison of Corneal Safety and Intraocular Pressure–Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions. Journal of Ocular Pharmacology and Therapeutics 30:4, pages 340-345.
Crossref
Crossref
Kati Kinnunen, Anu Kauppinen, Niina Piippo, Arto Koistinen, Elisa Toropainen & Kai Kaarniranta. (2014) Cationorm shows good tolerability on human HCE-2 corneal epithelial cell cultures. Experimental Eye Research 120, pages 82-89.
Crossref
Crossref
Yoshimi NiwanoAtsuo IwasawaMasahiko Ayaki. (2014) Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog. Ophthalmology and Eye Diseases 6, pages OED.S12445.
Crossref
Crossref
Madhiusudhan, LM Evelyn-Tai, Ishak Siti-Raihan & WH Wan Hazabbah. (2014) Stromal opacity secondary to preservative in dilating drops – A case report and review of literature. Journal of Acute Disease 3:1, pages 77-79.
Crossref
Crossref
Gemma Caterina Maria RossiMirella BliniLuigia ScudellerGabriella RicciardelliLaura DepoloAlberto AmisanoLaura BossolesiGian Maria PasinettiPaolo Emilio Bianchi. (2013) Effect of Preservative-Free Tafluprost on Keratocytes, Sub-Basal Nerves, and Endothelium: A Single-Blind One-Year Confocal Study on Naïve or Treated Glaucoma and Hypertensive Patients Versus a Control Group. Journal of Ocular Pharmacology and Therapeutics 29:9, pages 821-825.
Crossref
Crossref
Rajesh K. Rajpal, Raymond Fong & Timothy L. Comstock. (2013) Loteprednol Etabonate Ophthalmic Gel 0.5% Following Cataract Surgery: Integrated Analysis of Two Clinical Studies. Advances in Therapy 30:10, pages 907-923.
Crossref
Crossref
Zane Anwar, Sarah R. Wellik & Anat Galor. (2013) Glaucoma therapy and ocular surface disease. Current Opinion in Ophthalmology 24:2, pages 136-143.
Crossref
Crossref
Akihiko Okahara, Hidetoshi Tanioka, Koichi Takada & Kouichi Kawazu. (2013) Ocular Toxicity of Benzalkonium Chloride Homologs Compared with Their Mixtures. Journal of Toxicologic Pathology 26:4, pages 343-349.
Crossref
Crossref
Cory Swymer & Michael W Neville. (2012) Tafluprost: The First Preservative-Free Prostaglandin to Treat Open-Angle Glaucoma and Ocular Hypertension. Annals of Pharmacotherapy 46:11, pages 1506-1510.
Crossref
Crossref
Jess T. Whitson & W. Matthew Petroll. (2012) Corneal Epithelial Cell Viability Following Exposure to Ophthalmic Solutions Containing Preservatives and/or Antihypertensive Agents. Advances in Therapy 29:10, pages 874-888.
Crossref
Crossref